How to Get Addyi (Flibanserin) in Massachusetts

What Addyi Is and Why It Requires a Special Prescribing Process

Addyi is the only FDA-approved non-hormonal oral medication for hypoactive sexual desire disorder in premenopausal women. HSDD is defined by the DSM-5 as persistently low sexual desire that causes marked distress or interpersonal difficulty and is not explained by another medical condition, a relationship problem, or a medication effect. The FDA approved flibanserin in August 2015 after Sprout Pharmaceuticals resubmitted a risk-benefit analysis that included data from the BEGONIA trial and two other phase-3 studies enrolling more than 2,400 women. 1

Flibanserin is a 5-HT1A agonist and 5-HT2A antagonist that also has dopamine D4 partial-agonist activity. Unlike sildenafil, which acts peripherally on blood vessels, flibanserin modulates neurotransmitter balance in the prefrontal cortex. The net effect is a shift in the ratio of serotonin to dopamine and norepinephrine during periods of sexual arousal. The FDA's 2015 approval label describes this mechanism in the context of preclinical and clinical pharmacology data. 2

Because alcohol significantly amplifies the hypotension and syncope risk, the FDA placed flibanserin under a Risk Evaluation and Mitigation Strategy (REMS). Every prescriber must complete a free, 30-minute online training module before writing the first prescription. Patients sign a Patient-Provider Agreement Form at the time of prescribing. The REMS requirement does not restrict which prescriber type can write the prescription, and it does not require the patient to use a specialty pharmacy.

Who Can Prescribe Addyi in Massachusetts

Any Massachusetts-licensed prescriber with DEA registration and REMS certification may prescribe flibanserin. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Massachusetts General Laws Chapter 94C governs controlled substances, but flibanserin is not a controlled substance, so the prescription rules follow standard Schedule-unclassified drug law. 3

NPs in Massachusetts hold full practice authority under M.G.L. Chapter 112, Section 80B, which means an NP working independently through a telehealth platform can evaluate, diagnose HSDD, complete REMS certification, and issue the prescription without physician co-signature. PAs in Massachusetts prescribe under a supervising-physician agreement, but no additional approval layer is required specifically for flibanserin beyond that standard agreement and REMS completion.

Primary care physicians, OB-GYNs, psychiatrists, and sexual-medicine specialists all routinely prescribe Addyi. The ACOG Committee Opinion on female sexual dysfunction notes that primary care clinicians are well positioned to diagnose and manage HSDD because the workup does not require invasive testing. 4

Telehealth Prescribing for Addyi in Massachusetts

Massachusetts fully permits telehealth prescribing of flibanserin. The state's telehealth parity law (M.G.L. Chapter 175, Section 47BB) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services. Video visits are the standard modality. Some platforms also conduct audio-only visits for patients without reliable broadband, though video documentation is preferred for a new HSDD diagnosis.

The clinical workflow for a telehealth Addyi visit runs as follows. First, the patient completes a structured intake questionnaire, typically including the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS). Second, the prescriber conducts a synchronous video visit to confirm the HSDD diagnosis, review exclusion criteria (pregnancy, hepatic impairment, current CYP3A4-inhibitor use), and counsel on alcohol avoidance. Third, the prescriber completes REMS attestation and the patient signs the digital Patient-Provider Agreement. Fourth, the prescription routes to the patient's preferred pharmacy.

The FDA's REMS database confirms that telehealth-generated prescriptions are valid for flibanserin as long as the prescriber holds an active REMS certification. 3 Several national telehealth platforms serving Massachusetts patients list flibanserin as an available medication on their formulary pages, with visit fees ranging from approximately $75 to $149 out-of-pocket when insurance is not used.

Lab Work and Clinical Requirements Before Prescribing

No mandatory lab panel is required by the FDA or the Addyi REMS before starting flibanserin. The clinical assessment is primarily history-based. A thorough prescriber will still check specific items to rule out secondary causes of low desire. 5

Tests a thorough prescriber orders before starting flibanserin:

• Thyroid-stimulating hormone (TSH): Hypothyroidism suppresses libido. The American Thyroid Association recommends TSH as first-line thyroid screening. 6
• Total and free testosterone: Low androgen levels can mimic HSDD. The Endocrine Society notes that a morning total testosterone <25 ng/dL in a premenopausal woman may warrant further evaluation. 7
• Prolactin: Hyperprolactinemia from a pituitary microadenoma suppresses desire; a fasting serum prolactin rules this out quickly.
• Comprehensive metabolic panel (CMP): Flibanserin is metabolized by CYP3A4 and CYP2C19 in the liver. Hepatic impairment is a contraindication. The FDA label states that flibanserin AUC increased 4.5-fold in patients with hepatic impairment compared to healthy controls. 2
• Pregnancy test (urine or serum hCG): Addyi is approved for premenopausal women and is not studied in pregnancy.

A full medication reconciliation is as important as any lab result. Moderate or strong CYP3A4 inhibitors, including fluconazole, clarithromycin, and grapefruit juice consumed in large quantities, raise flibanserin plasma concentrations and require discontinuation before starting therapy. The FDA label lists the contraindicated co-medications explicitly. 2

Clinical Efficacy Data: What Patients Should Expect

The BEGONIA trial (N=1,378) randomized premenopausal women with HSDD to flibanserin 100 mg nightly or placebo for 24 weeks. Women in the flibanserin arm reported a statistically significant increase in the number of satisfying sexual events (SSEs) per month compared to placebo (treatment difference: +0.7 SSEs/month, P<0.001) and a meaningful reduction in HSDD-related distress on the Female Sexual Distress Scale-Revised (FSDS-R). 1

The SNOWDROP trial, a companion phase-3 study (N=949), found a similar SSE benefit at 24 weeks and confirmed that most responders saw improvements between weeks 4 and 8 of treatment. 8

Pooled data from the three key trials (N=2,400+) showed that approximately 10% of patients discontinued due to adverse effects, most commonly dizziness, somnolence, nausea, and fatigue. Serious hypotension occurred in <1% of patients not consuming alcohol. 2

Clinicians should counsel patients that flibanserin is not a "female Viagra." It does not produce an acute arousal response. It changes the neurochemical baseline over weeks. A reasonable trial period is 8 weeks at consistent nightly dosing before assessing response.

MassHealth (Medicaid) Prior Authorization for Addyi

MassHealth covers Addyi with prior authorization for eligible premenopausal women. The PA process follows a specific documentation checklist that prescribers must compile before submission. 9

Standard MassHealth PA documentation requirements for flibanserin:

1. Confirmed DSM-5 diagnosis of HSDD (ICD-10 code F52.0), documented in a clinical note.
2. Duration of symptoms: MassHealth typically requires at least 6 months of documented low desire causing distress.
3. Exclusion of secondary causes: the prescriber must note that thyroid disease, hyperprolactinemia, depression, and relationship factors have been assessed.
4. Medication history: documentation that the distress is not attributable to an SSRI, SNRI, or combined oral contraceptive, or that those agents have been adjusted without resolution.
5. Prescriber REMS certification number.
6. Signed Patient-Provider Agreement Form.

PA decisions for MassHealth are typically returned within 3 to 7 business days for standard review. Urgent PA, available when the prescriber documents medical necessity, resolves within 72 hours. If MassHealth denies the initial PA, the prescriber may submit a peer-to-peer review request within 30 days of the denial.

Commercial insurers in Massachusetts vary widely. Blue Cross Blue Shield of Massachusetts lists flibanserin on its non-preferred brand tier with PA for most commercial plans. Patients paying out-of-pocket can use the Sprout Pharmaceuticals savings card, which may reduce the 30-tablet retail cost (approximately $900 to $1,100 without insurance) to as low as $99 per month for commercially insured patients.

Pharmacy Access: Retail, Mail-Order, and 503A Compounding in Massachusetts

Retail and mail-order pharmacies. Flibanserin is not a controlled substance and does not require a specialty pharmacy under the REMS. Any Massachusetts-licensed retail pharmacy that stocks the product can dispense it. CVS, Walgreens, and Rite Aid locations across the state carry Addyi or can order it within 24 to 48 hours. Mail-order pharmacies under commercial insurance plans (Express Scripts, CVS Caremark, OptumRx) dispense 90-day supplies, which reduces per-unit cost. 3

503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed compounding pharmacies to prepare patient-specific, non-commercially available formulations when a prescriber writes a specific order for an individual patient. Massachusetts-licensed 503A pharmacies may compound flibanserin for documented patient-specific needs, such as a patient with a documented excipient allergy to an ingredient in the commercial tablet. The Massachusetts Board of Registration in Pharmacy licenses and inspects 503A compounders. 10

Patients should confirm with any compounding pharmacy that it holds a current Massachusetts Board of Registration in Pharmacy license and that the compound has been prepared from USP-grade active pharmaceutical ingredient. Compounded flibanserin is not covered by most insurance plans because it lacks an NDC code; cost is typically $60 to $180 for a 30-day supply depending on the formulation and pharmacy.

Transfer of an out-of-state prescription. Massachusetts law permits transfer of a non-controlled-substance prescription to any in-state pharmacy, provided no refills have been dispensed at the original pharmacy and the original prescription has not expired. A patient relocating from another state with a valid flibanserin prescription can call any Massachusetts-licensed retail or mail-order pharmacy to initiate a transfer. The receiving pharmacist contacts the original dispensing pharmacy directly.

Timing: How Long Until the First Dose

For a telehealth visit with same-day prescriber availability, the typical timeline is:

• Day 0: Video visit completed, REMS forms signed, prescription sent electronically.
• Day 1: Retail pharmacy fills the prescription same-day or next-day if stock is on hand. Mail-order shipment takes 3 to 5 business days.
• Day 2 to 3 (with insurance): PA for commercial insurance or MassHealth adds 3 to 7 business days unless the prescriber submits urgent PA documentation.

Patients starting therapy should take the first dose on a Friday or Saturday night to allow the first few nights of potential dizziness and somnolence to occur on days off from work. This timing suggestion aligns with the product labeling recommendation to initiate at bedtime. 2

Drug Interactions and Safety Counseling Specific to Massachusetts Patients

The alcohol interaction is the single most discussed safety issue with flibanserin, and it requires explicit, documented counseling at every prescribing visit. In a pharmacokinetic study of 25 healthy volunteers, co-administration of flibanserin with alcohol produced symptomatic hypotension in 6 of 23 assessable subjects and syncope in 2 subjects. 2 The risk is bidirectional: alcohol consumed up to 2 hours before bedtime or within 8 hours after the dose amplifies CNS depression.

Additional interactions requiring prescriber attention:

• CYP3A4 inhibitors (strong): ketoconazole, itraconazole, clarithromycin, nefazodone, ritonavir, and others listed in the FDA label are contraindicated. 2
• CYP3A4 inhibitors (moderate): fluconazole (commonly prescribed for vulvovaginal candidiasis in this patient population), ciprofloxacin, diltiazem, verapamil. The label recommends avoiding moderate inhibitors; if co-administration is medically necessary, the prescriber should lower the flibanserin dose and monitor closely.
• CNS depressants: benzodiazepines, sedating antihistamines, and muscle relaxants compound somnolence risk.
• Hormonal contraceptives: ethinyl estradiol-containing oral contraceptives mildly inhibit CYP3A4. The pharmacokinetic interaction is modest (flibanserin AUC increases approximately 40%), but the combination does not require dose adjustment per the current label. 2

Prescribers in Massachusetts should document the drug-interaction and alcohol counseling in the visit note. This documentation supports PA approval and protects against medicolegal risk.

Monitoring After Starting Flibanserin

Flibanserin does not require routine laboratory monitoring once initiated. The clinical follow-up schedule most consistent with the trial protocols and FDA labeling is:

• 4 weeks: Assess tolerability. Dizziness, somnolence, and nausea peak in the first 2 weeks and typically attenuate by week 4. If side effects persist at week 4, consider dose timing adjustment (some patients tolerate 2 to 3 hours before planned sleep better than immediately at bedtime).
• 8 weeks: Assess efficacy. Women who report no improvement in SSE frequency or desire-related distress scores at 8 weeks have a low probability of late response. The North American Menopause Society recommends reassessing benefit and risk at least every 6 months for any prescribed HSDD therapy. 11
• Ongoing: If the patient starts a new CYP3A4 inhibitor (for example, a course of fluconazole for recurrent yeast infections), the prescriber should temporarily hold flibanserin during that treatment course and for 3 days after the inhibitor is stopped.

The HealthRX clinical team uses a structured four-item check at every flibanserin follow-up visit: (1) SSE frequency change from baseline, (2) FSDS-R distress score, (3) side-effect inventory with explicit alcohol-use re-screening, and (4) medication reconciliation for new CYP3A4 inhibitors or CNS depressants. This four-item framework can be completed in under 8 minutes during a telehealth check-in and documents the clinical rationale for continuation or discontinuation.

Comparing Flibanserin to Other HSDD Treatments Available in Massachusetts

Flibanserin is one of two FDA-approved pharmacologic treatments for HSDD. The other is bremelanotide (Vyleesi), a subcutaneous melanocortin receptor agonist approved in 2019 for use on-demand rather than daily. 12 Bremelanotide is self-injected 45 minutes before anticipated sexual activity. It carries its own set of contraindications, including cardiovascular disease, and produces transient blood pressure increases rather than decreases.

Off-label options sometimes discussed in Massachusetts clinical settings include testosterone (not FDA-approved for women in the United States) and bupropion (FDA-approved for depression but studied off-label for SSRI-induced sexual dysfunction in women). A 2012 Cochrane review found insufficient evidence to recommend testosterone for premenopausal HSDD outside a clinical trial setting. 13

The ACOG Committee Opinion on female sexual dysfunction states: "Clinicians should recognize that HSDD is a medical diagnosis requiring a thorough biopsychosocial evaluation. Pharmacologic treatment should be considered alongside sex therapy referral, not as a replacement for it." 4

Sex therapy with a licensed clinician, cognitive behavioral approaches, and couples counseling have evidence for improving desire-related distress and can be combined with flibanserin without pharmacokinetic concerns.

Step-by-Step Guide to Getting Addyi in Massachusetts Today

1. Confirm eligibility. You are a premenopausal woman with persistent low sexual desire causing personal distress, no hepatic impairment, no current use of contraindicated CYP3A4 inhibitors, and a willingness to avoid alcohol around each dose.
2. Choose a prescriber. Book a telehealth visit with a Massachusetts-licensed NP, PA, MD, or DO who offers HSDD evaluation. HealthRX providers complete REMS certification before your visit.
3. Complete the intake forms. The DSDS and a full medication list are standard. Honest answers about alcohol use are medically necessary.
4. Attend the video visit. The prescriber confirms the HSDD diagnosis, reviews labs if not recently done, and counsels on the alcohol interaction. You sign the Patient-Provider Agreement digitally.
5. Select a pharmacy. Provide your preferred retail pharmacy or request mail-order. If you have MassHealth or commercial insurance requiring PA, the prescriber submits PA documentation the same day.
6. Pick up or receive your prescription. Without PA, expect same-day to next-day fill at a retail pharmacy. With PA, allow 3 to 7 business days.
7. Take the first dose on a low-obligation night. 100 mg at bedtime. No alcohol that evening or the following morning.
8. Follow up at 4 weeks and 8 weeks to assess tolerability and early efficacy.

Patients who experience no benefit at 8 weeks of consistent nightly use should schedule a follow-up to discuss bremelanotide, off-label options, or referral to a sexual-medicine specialist.